<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571959</url>
  </required_header>
  <id_info>
    <org_study_id>IMEA 046</org_study_id>
    <nct_id>NCT02571959</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of the Association of Amoxicillin / Clavulanic Acid to Obese Adults</brief_title>
  <acronym>PHACO</acronym>
  <official_title>Pharmacokinetic Study of the Amoxicillin / Clavulanic Acid Association to Optimize Dosage Among Obese Adults (PHACO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Description of the pharmacokinetic parameters of the amoxicillin / clavulanic acid to healthy
      voluntary obese after oral and intra venous administration Determination of the
      pharmacokinetic parameters of amoxicillin / clavulanic acid obtained from plasmatic
      concentrations of intravenous injection (IV) and oral administrations. The criterion of
      evaluation allowing to answer our main objective corresponds to the parameters estimated by
      the pharmacokinetic model of the concentrations obtained from the data IV and by the
      pharmacokinetic model of the concentrations obtained from the oral data. The following
      pharmacokinetic parameters will be considered at every obese volunteer's for both molecules
      (amoxicillin and clavulanic acid) from the concentrations by pharmacokinetic analysis of
      population.

      The main evaluation criteria are PK parameters of amoxicillin / clavulanic:

        -  Cl, systematic plasmatic clearance

        -  Vd, volume of distribution

        -  ASC 0-oo, area under the curve time - concentration

        -  T1/2, half-life time

        -  F, bioavailability after oral administration

        -  Ka, constant of speed of absorption
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective Description of the pharmacokinetic parameters of the amoxicillin / clavulanic
      acid to healthy voluntary obese after oral and intra venous administration

      Secondary objectives

        -  Define dosage plans optimized with the antibiotic treatment to the obese subject

        -  Ensure an adequacy of the treatment with the related infection

        -  Formulate recommendations of dosage adaptations for a better individualization of
           treatments, by estimating several plans of doses by simulation to reach various PK/PD
           goals according to different theoretical MIC

      Methodology

      The pharmacokinetic analysis will be realized by approach of population allowing the
      estimation of the average parameters of amoxicillin and clavulanic acid as well as the
      interpersonal variability after an administration IV and an oral administration. Parameters's
      population and their variability will be estimated with the SAEM algorithm implemented in the
      software Monolix ( www.lixoft.eu ).

      For the main objective, PK parameters PK of amoxicillin and clavulanic acid will be
      determined to day 1 and day 2. They will be described by means of indicators of position
      (average and median) and of dispersal (standard deviations, quartiles).

      For secondary objectives, the profiles concentration/time of 1000 obese subjects will be
      determined by Monte Carlo method from PK parameters estimated at the balance by the model.
      For every feigned profile, the time during which the plasmatic concentration of amoxicillin
      and clavulanic acid is superior to a panel of theoretical MIC will be calculated by means of
      curves concentration - time determined for each of the subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2015</start_date>
  <completion_date type="Actual">June 16, 2017</completion_date>
  <primary_completion_date type="Actual">October 13, 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systematic plasmatic clearance (Cl)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve time - concentration (AUC 0-oo)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life time (T1/2)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability after oral administration (F)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constant of speed of absorption (Ka)</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>amoxicillin and clavulanic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All volunteers receive a dose of amoxicillin and clavulanic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin and clavulanic acid</intervention_name>
    <description>Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered</description>
    <arm_group_label>amoxicillin and clavulanic acid</arm_group_label>
    <other_name>AMOXICILLINE / acide clavulonique SANDOZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin and clavulanic acid</intervention_name>
    <description>Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route</description>
    <arm_group_label>amoxicillin and clavulanic acid</arm_group_label>
    <other_name>AMOXICILLINE / acide clavulonique SANDOZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary obese

          -  Body mass index upper to 30 kg/m2

          -  Age from 18 to 65 years

          -  Signed free and lit consent

          -  Possible participation according to the national file of the volunteers of the French
             Ministry of Health.

          -  Volunteers affiliated to the Social Security

        Exclusion Criteria:

          -  Pregnancy

          -  Evolutionary pregnancy or feeding

          -  Allergy in ß-lactamines (nettle rash, oedema of Quincke)

          -  Digestive intolerance with amoxicillin / clavulanic acid

          -  Infection by the virus of the HIV ( positive Ac anti HIV)

          -  Infection by the virus of the hepatitis B ( positive Ag Hbs)

          -  Infection by the virus of the hepatitis C ( positive Ac anti VHC)

          -  Hepatic cirrhosis at the Child-Pugh C stage(stadium)

          -  Biological parameters:

          -  Polynucléaires neutrophiles 750 / mm3

          -  Haemoglobin 8g / dL

          -  Patellets 60 000 / mm3

          -  Creatinin clearance, according to MDRD, DFG 50 mL / min / 1,73m2

          -  ASAT or ALAT &gt; 3 times the superior limit of the normal (LSN)

          -  Phosphatase alkaline &gt; 3 LSN

          -  Total Bilirubine &gt; 3 LSN

          -  Lipase &gt; 3 LSN

          -  Factor V &lt; 50 %

          -  Alcoholism chronicles (consumption superior to 30 g of alcohol a day, amount to 3
             glasses of wine)

          -  Significant anomaly of the electrocardiogram, in particular QTc &gt; 450 msec

          -  Subject susceptible not to respect the modalities of the study

          -  Drug addiction intra venous

          -  Any medical conditions which according to the judgment(sentence) of the investigator
             would may interfere with the moderate pharmacokinetic parameters

          -  People placed under legal protection

          -  Histories of bariatric surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Ambroise Pare</name>
      <address>
        <city>Boulogne</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Pharmacology</keyword>
  <keyword>Amoxicillin-Potassium Clavulanate Combination</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

